Monthly updates with the latest on adherence from health psychology academics and industry leaders Read More
The development of new therapeutic agents is set to revolutionise treatment of hepatitis C (HCV). The current standard treatment can be demanding physically, emotionally and practically for those patients who initiate it. The new therapies represent a real transformation in care; they have fewer, milder side effects, a shorter treatment duration, a simpler regimen and dramatically improved success rates compared with current treatments1. While the development of new treatments is positive, it raises fresh questions around adherence and supporting patients to achieve optimal results.